CCL22 and COVID-19: In particular, in our cohort, the plasma levels of two multiple pro-inflammatory chemokines, MIP-1b and MDC, were increased in patients with moderate COVID-19 compared to HDs, but had no differences between patients with severe COVID-19 and HDs.